Breast growth caused by spironolactone is often reversible if the drug is stopped relatively early, but tissue that has been developing for roughly a year or longer can become permanent. The distinction hinges on what kind of tissue has formed: early-stage growth is mostly swollen, hormonally stimulated glandular tissue that can shrink back, while prolonged growth leads to structural changes that do not undo themselves. Whether you are a man dealing with an unwanted side effect, a woman noticing breast tenderness on a dermatology prescription, or a transgender woman hoping the growth sticks around, the timeline matters more than almost any other variable.
Why Spironolactone Triggers Breast Growth in the First Place
Spironolactone is a potassium-sparing diuretic prescribed for conditions ranging from heart failure and high blood pressure to hormonal acne and hair loss. It also blocks androgen receptors and has weak estrogen-like activity, which shifts the balance between estrogen and androgen signaling in the body. That hormonal imbalance is what drives breast tissue to proliferate. In men, this shows up as gynecomastia, a benign enlargement of glandular breast tissue that can be tender or painful. In women, the effect is subtler because estrogen already dominates, but breast swelling and tenderness still occur in some people.
The antiandrogenic properties are precisely what make spironolactone useful for acne and androgenic hair loss in women, and why it is commonly prescribed as part of feminizing hormone therapy for transgender women. The breast growth is, depending on who you are, either the main complaint or part of the goal.
How Reversible Is the Growth After Stopping the Drug?
Case reports consistently show that breast enlargement from spironolactone can shrink once the medication is discontinued, particularly when the growth has been present for a limited time. In one published case, a man developed painful breast swelling on one side after about 12 months of spironolactone treatment; within a month of stopping the drug, the pain went away and the swelling began to decrease in size.1PubMed Central. Spironolactone-Induced Unilateral Gynecomastia In another case report, a patient’s gynecomastia fully resolved within three months of discontinuing spironolactone.2CMAJ. Spironolactone-induced gynecomastia
These are encouraging outcomes, but they come with a major caveat: they were caught and addressed before the tissue had undergone permanent structural changes. The pattern in the clinical literature is that early-stage gynecomastia responds well to drug withdrawal, while established, longer-standing growth does not.
The Roughly 12-Month Threshold
The general clinical consensus is that gynecomastia lasting longer than about 12 months becomes unlikely to reverse on its own. Over time, the tissue transitions from active glandular proliferation, which is hormonally sensitive and can shrink, to fibrotic tissue that has essentially remodeled itself into a more permanent structure. Once that fibrosis sets in, removing the hormonal stimulus by stopping spironolactone will not make the breast tissue go away.3PubMed Central. Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review
This 12-month figure is not a precise cutoff but a rough guideline based on the biology of breast tissue remodeling. Some people may hit the irreversible stage sooner; others may retain some degree of reversibility longer. The point is that time is the critical variable. If you notice breast changes on spironolactone and want them to go away, the sooner you discuss it with your prescriber, the better your chances of the tissue regressing naturally after a medication change.
Does Dose Matter?
Higher doses of spironolactone are associated with more pronounced hormonal side effects, including breast changes. The drug has been prescribed across a wide range of doses: as low as 25 mg per day for mild fluid retention or acne, and as high as 200 to 400 mg per day for severe heart failure or as part of feminizing hormone therapy. The antiandrogenic effects scale with the dose, so a person taking 25 mg for acne has substantially less hormonal disruption than someone on 200 mg for another condition.
Among cisgender women using spironolactone for dermatological conditions, breast swelling appears to be quite rare. A retrospective analysis of adverse events reported to the FDA found that breast swelling accounted for only about 0.1% of reported side effects in women.4PubMed Central. Retrospective analysis of adverse events with spironolactone in females reported to the United States Food and Drug Administration Breast tenderness is somewhat more common than actual enlargement, and most women on lower dermatological doses never experience clinically meaningful breast growth at all.
For cisgender men, the story is different. Even moderate doses of spironolactone prescribed for heart failure or liver disease can trigger gynecomastia, because blocking androgen receptors in someone whose hormonal baseline relies heavily on androgens produces a more dramatic shift. The breast growth seen in men is recognized as a direct consequence of the drug’s antiandrogenic mechanism.5PubMed Central. Spironolactone-Induced Bilateral Gynecomastia in a Patient With Comorbid Conditions
Breast Growth in Transgender Women on Spironolactone
For transgender women, spironolactone is commonly used alongside estradiol as an antiandrogen to support feminization. In this context, breast development is a desired outcome rather than a side effect. A natural question is how much breast growth spironolactone actually contributes on top of estrogen therapy, and whether it is more or less effective than other antiandrogens.
A randomized clinical trial directly compared spironolactone to cyproterone acetate (another antiandrogen) in transgender women starting estradiol. At six months, the average breast volume was roughly 158 mL in the spironolactone group and about 190 mL in the cyproterone acetate group, a difference that was not statistically meaningful. Both groups had an average calculated cup size of AAA, with individual variation ranging dramatically from barely any growth to a B cup.6The Journal of Clinical Endocrinology & Metabolism. Effect of Spironolactone and Cyproterone Acetate on Breast Growth in Transgender People: A Randomized Clinical Trial That wide range underscores something important: genetics, body composition, and individual hormonal sensitivity play a huge role in how much breast tissue develops, regardless of which antiandrogen is used.
A systematic review of antiandrogens in transgender women found that no studies had adequately evaluated the effects of these drugs specifically on breast development. While cyproterone acetate and certain other antiandrogens may suppress testosterone levels more effectively than spironolactone, it remains unclear whether that translates into meaningfully different feminization outcomes, because spironolactone works partly by blocking the androgen receptor directly rather than just lowering testosterone levels.7PubMed. A systematic review of antiandrogens and feminization in transgender women
For transgender women wondering whether breast growth achieved on spironolactone and estradiol will persist if they later stop the antiandrogen but continue estrogen, the answer is generally yes for established tissue. The same biology applies: once breast tissue has fully developed and matured, it tends to stay, because mature breast tissue in anyone is structurally stable. What may change is the fullness or volume if hormonal levels shift, similar to how cisgender women’s breasts fluctuate somewhat with hormonal changes throughout life. But the underlying glandular and structural tissue does not disappear.
When Breast Growth Sticks Around and Surgery Becomes the Conversation
For men with long-standing gynecomastia that has not responded to stopping spironolactone, the remaining options are pharmacological or surgical. Some clinicians have used drugs like tamoxifen to try to reduce established gynecomastia, though these treatments work best in the early, active-growth phase rather than after fibrosis has occurred. Experts in the field have noted that surgical approaches, including liposuction or excision, are generally considered for patients with gynecomastia that has lasted long enough to become irreversible, or that is causing significant distress or reduced quality of life.3PubMed Central. Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review
Surgery is straightforward in concept but is typically reserved for cases where other options have been exhausted. For most people, the first step is always to stop or switch the offending medication and wait several months to see how much the tissue regresses on its own.
Alternatives That Avoid the Hormonal Side Effects
If you need the fluid-removing or blood-pressure-lowering effects of spironolactone but not the hormonal baggage, newer mineralocorticoid receptor antagonists exist. Eplerenone and finerenone are both used in similar clinical settings but have far less affinity for androgen and estrogen receptors. A pharmacovigilance study comparing safety profiles of the three drugs across two decades of FDA adverse-event data found that spironolactone was uniquely associated with sex-hormone-related side effects, including gynecomastia and other endocrine disruptions, while eplerenone and finerenone lacked significant signals for those effects.8PubMed Central. Comparative safety profiles of spironolactone, eplerenone, and finerenone: a pharmacovigilance study based on FAERS data from 2004 to 2024
The tradeoff is that eplerenone and finerenone do not offer the antiandrogenic benefits that make spironolactone useful for acne, hair loss, and feminizing hormone therapy. For those indications, the hormonal activity is the point, not a bug. But for a man on spironolactone for heart failure who develops uncomfortable breast enlargement, switching to eplerenone is a reasonable conversation to have with a cardiologist.
Common Misconceptions About Spironolactone and Breasts
One widespread misunderstanding is that any breast tenderness on spironolactone means permanent growth is happening. Tenderness and mild swelling, especially in the first few weeks of starting the drug, are common and do not necessarily indicate significant tissue proliferation. Many people experience cyclical tenderness that comes and goes without any lasting size change. Actual glandular growth takes months of sustained hormonal imbalance to develop.
Another misconception, common in online transgender health forums, is that spironolactone is the primary driver of breast development in feminizing therapy. The estrogen component is what does the heavy lifting for breast growth. Spironolactone’s role is mainly to reduce the interfering effects of testosterone, creating a hormonal environment where estrogen can do its work more effectively. The randomized trial data showing roughly similar breast development between spironolactone and cyproterone acetate groups supports this interpretation: the antiandrogen’s specific identity matters less than whether androgens are sufficiently suppressed.6The Journal of Clinical Endocrinology & Metabolism. Effect of Spironolactone and Cyproterone Acetate on Breast Growth in Transgender People: A Randomized Clinical Trial
A third misunderstanding is that stopping spironolactone immediately reverses all hormonal effects. While the drug clears the body within a day or two, the tissue changes it promoted do not reverse on that timeline. Breast tissue regression, when it happens, is a slow process that unfolds over weeks to months. Patience is required, and expectations should be set accordingly.
What to Watch for If You Are on Spironolactone
If you are taking spironolactone for any reason and notice breast changes you did not expect or want, the practical steps are straightforward. Note when the changes started and whether they involve pain, firmness, or visible enlargement. Bring it up with your prescriber sooner rather than later; waiting months while hoping it resolves on its own is exactly the wrong strategy, given that the window for easy reversibility narrows over time. Your doctor may reduce the dose, switch you to a different medication, or monitor the situation depending on how essential spironolactone is for your primary condition.
If you are a transgender woman on spironolactone and estradiol, keep in mind that breast development is a slow process that typically continues for two to three years of hormone therapy. Six months of treatment produces modest results on average, as the trial data showed with most participants in the AAA-cup range at that point.9Journal of the Endocrine Society. 5065 Cyproterone Acetate Versus Spironolactone In Transgender Women Commencing Estradiol: A Randomized Controlled Trial The enormous individual variation, from barely measurable to a B cup in that same trial, means that your experience may diverge significantly from averages. Comparing your results to others at the same point in treatment is not especially informative.
For cisgender women using spironolactone for acne or hair loss at typical dermatological doses, meaningful breast enlargement is uncommon enough that it should not be a primary concern when deciding whether to take the medication. Breast tenderness is more likely but usually manageable and often temporary. If actual growth occurs, the same reversibility principles apply: earlier discontinuation gives better odds of regression.
The Role of Age and Underlying Health
Older adults tend to have lower baseline levels of sex hormones, which means the hormonal disruption caused by spironolactone can be proportionally larger. Men with liver disease, who are commonly prescribed spironolactone for fluid retention, are already at higher risk for gynecomastia because liver dysfunction impairs the metabolism of estrogen. Adding an antiandrogenic drug on top of an already estrogen-heavy hormonal profile makes breast growth more likely and potentially faster to develop.
The case reports in the literature often involve men in their fifties or older with conditions like cirrhosis or chronic heart failure, precisely the populations where the hormonal environment is already primed for breast tissue growth.1PubMed Central. Spironolactone-Induced Unilateral Gynecomastia Younger, otherwise healthy individuals taking spironolactone for dermatological reasons are less vulnerable simply because their baseline hormonal balance is more robust and harder to tip.
Body fat percentage also plays a role, since adipose tissue contains aromatase, an enzyme that converts androgens into estrogens. Someone with more body fat produces more peripheral estrogen, so the addition of an antiandrogen like spironolactone amplifies an existing tendency. This is one reason why the same dose of the same drug can produce very different breast outcomes in different people, and why predicting exactly who will develop significant breast growth remains difficult.